The first claims of the issued U.S. patents are very broad,
and virtually every company that is doing proteomics of any
value infringes that claim, IMO.
I don't follow trickle companies closely. There was a
company that actually sold equipment for 2-D gels that went
public and then got gobbled?? I'll look for "risk factor"
discussions in SEC filings.
No wonder I've felt this "what the hell is going on" frustration before (PERSEUS LLC, 13F-HR, 11/14/2002).......
FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
---------------------------------- --------- --------- ---------- -------------------- ---------- -------- ----------------------
VOTING
AUTHORITY
TITLE SHRS OR SH/ PUT/ INVESTMENT OTHER ----------------------
NAME OF ISSUER OF CLASS CUSIP VALUE (x$) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE
---------------------------------- --------- --------- ---------- --------- --- ---- ---------- -------- --------- ------ ----
------------------------------------------------------------------------------------------------------------------------------------
InSite Vision Incorporated Common 457660108 $1,112 1,002,245 SH DEFINED 1,002,245
------------------------------------------------------------------------------------------------------------------------------------
IntraBiotics Pharmaceuticals, Inc. Common 46116T100 $564 1,225,209 SH DEFINED 1,225,209
------------------------------------------------------------------------------------------------------------------------------------
La Jolla Pharmaceutical Company Common 503459109 $4,402 1,033,265 SH DEFINED 1,033,265
------------------------------------------------------------------------------------------------------------------------------------
Landec Corporation Common 514766104 $547 252,048 SH DEFINED 252,048
------------------------------------------------------------------------------------------------------------------------------------
Neurobiological Technologies, Inc. Common 64124W106 $1,622 553,750 SH DEFINED 553,750
------------------------------------------------------------------------------------------------------------------------------------
Novoste Corp. Common 67010C100 $454 97,900 SH DEFINED 97,900
------------------------------------------------------------------------------------------------------------------------------------
Oxford GlycoSciences Plc Sponsored 691464101 $1,080 474,698 SH DEFINED 474,698
ADR
------------------------------------------------------------------------------------------------------------------------------------
Proton Energy Systems Inc. Common 74371K101 $1,514 714,286 SH DEFINED 714,286
------------------------------------------------------------------------------------------------------------------------------------
Roxio Inc. Common 780008108 $233 76,749 SH DEFINED 76,749
------------------------------------------------------------------------------------------------------------------------------------
Sciclone Pharmaceuticals Inc. Common 80862K104 $3,711 1,257,860 SH DEFINED 1,257,860
------------------------------------------------------------------------------------------------------------------------------------
Targeted Genetics Corporation Common 87612M108 $114 200,000 SH DEFINED 200,000
------------------------------------------------------------------------------------------------------------------------------------
Texas Biotechnology Corporation Common 88221T104 $1,224 400,000 SH DEFINED 400,000
------------------------------------------------------------------------------------------------------------------------------------
Versicor, Inc. Common 925314106 $409 48,000 SH DEFINED 48,000
------------------------------------------------------------------------------------------------------------------------------------
ViroPharma Incorporated Common 928241108 $587 581,043 SH DEFINED 581,043
------------------------------------------------------------------------------------------------------------------------------------ |
